Vertaile menetelmiä

	Schild-analyysi	Isobologram-analyysi	Michaelis-Mentenin kinetiikka	Populaatiofarmakodynaaminen mallinnus
Tieteenala	Farmakologia	Farmakologia	Farmakologia	Farmakologia
Menetelmäperhe	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
Syntyvuosi	1947	1926	1913	1992
Kehittäjä	Henry Schild	Salvatore Loewe	Leonor Michaelis and Maud Menten	Lewis Sheiner and Stephen Roush
Tyyppi	antagonism quantification	synergy quantification	mechanistic model	dose-response modeling
Alkuperäislähde	Schild, H. O. (1947). pA, a new scale for the measurement of drug antagonism. Journal of Physiology, 106(3), 337-357.	Loewe, S. (1926). Die Mischtoxizität. Zeitschrift für Experimentelle Pathologie und Therapie, 24, 315-334.	Michaelis, L., & Menten, M. L. (1913). Die Kinetik der Invertinwirkung. Biochemische Zeitschrift, 49, 333-369.	Dahlström, B., & Nyberg, L. (1993). Population pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics, 24(1), 45-57.
Rinnakkaisnimet	Schild plot, pA2	isobol, combination index, synergy testing	MM kinetics, Michaelis constant, Vmax	PopPD, population PD, hierarchical PD modeling
Liittyvät	3	3	2	3
Tiivistelmä	Schild analysis is a quantitative method for characterizing competitive receptor antagonism developed by Henry Schild in 1947. It uses dose-response curves in the presence and absence of antagonist to estimate the antagonist affinity constant (pA2), enabling standardized comparison of antagonist potency across drugs and experimental systems.	Isobologram analysis is a graphical and quantitative method for detecting and classifying drug interactions, developed by Salvatore Loewe in 1926. It uses dose-response data from two drugs applied individually and in combination to determine whether their interaction is additive, synergistic, or antagonistic.	Michaelis-Menten kinetics describes the rate of enzyme-catalyzed reactions as a function of substrate concentration. Developed by Leonor Michaelis and Maud Menten in 1913, this foundational framework models enzyme catalysis through the rapid-equilibrium approximation and enables prediction of drug metabolism rates in pharmacokinetics.	Population pharmacodynamic (PopPD) modeling integrates pharmacokinetics with individual dose-response relationships across patient populations to characterize drug efficacy and tolerability. Pioneered by Lewis Sheiner and colleagues, PopPD accounts for inter-individual variability in drug effects and enables rational dose optimization and response prediction.